4Q Financial Reports: Pfizer

Pfizer

4Q Revenues: $13.6 billion (-9%)

4Q Earnings: $2.7 billion (-3%)

FY Revenues: $51.3 billion (-2%)

FY Earnings: $8.1 billion (-29%)

Comments: Human Health revenue declined 4% for the year due to U.S. generic competition for certain key medicines, uncertainty related to Celebrex, and the suspension of Bextra sales. Celebrex sales were down 53% to $472 million for the quarter. Lipitor sales were up 3% to $3.4 billion for the quarter, and up 12% to $12.2 billion for the year. Norvasc sales were down 1% to $1.2 billion for the quarter and sales for the year were up 5% to $4.7 billion. Caduet sales reached $65 million for the quarter, up from $15 million 4Q2004. The company launched Lyrica, an anti-epileptic drug, in the U.S. in September 2005.